AmpliChip for cytochrome P-450 genotyping: The epoch of personalized prescriptions

Hospital Pharmacy

Volumn 41, Issue 5, 2006, Pages 442-454

  Gates, Brian J ^a   Davies, Neal M ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Amplichip; Genotyping; Pharmacogenomics; Polymorphisms

Indexed keywords

EID: 34548228302     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4105-442     Document Type: Review

References (63)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279: 1200-1205. (Pubitemid 28193431)
2. Johnson JA, Bootman JL. Drug-related morbidity and mortality. Arch Intern Med. 1995;155:1949-1956.
3. Nelson DR, Kamataki T, Waxman DJ, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 1993;12:1-51. (Pubitemid 23064489)
4. Eichelbaum M, Evert B. Influence of pharmacogenetics on drug disposition and response. Clin Exp Pharmacol Physiol. 1996;23:983-985. (Pubitemid 26361726)
5. Kitada M. Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6. Int J Clin Pharmacol Res. 2003;23:31-35. (Pubitemid 37339363)
6. Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet. 2004;43:553-576. (Pubitemid 38951800)
7. Drescher S, Schaeffeler E, Hitzl M, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol. 2002;53:526-534. (Pubitemid 34527155)
8. Verstuyft C, Schwab M, Schaeffeler E, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol. 2003;58:809-812. (Pubitemid 36577811)
9. Bonicke R, Reif W. Enzymatische inaktivierung von isonicotinsaurehydrazid im menschlichen und tierischen organismus. Arch Exper Pathol Pharmakol. 1953;220:321.
10. Hughes HB, Biehl JP, Jones AP, Schmidt LH. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc. 1954;70:266-273.
11. Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002;35:883-889.
12. Das KM, Eastwood MA, McManus JP, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973;289:491-495.
13. Dupret JM, Rodrigues-Lima F. Structure and regulation of the drugmetabolizing enzymes arylamine Nacetyltransferases. Curr Med Chem. 2005;12:311-318. (Pubitemid 40305622)
14. Grant DM, Goodfellow GH, Sugamori K, Durette K. Pharmacogenetics of the human arylamine N-acetyltransferases. Pharmacology. 2000;61:204-211.
15. D'amato M, Vitiani LR, Petrelli G, et al. Association of persistent bronchial hyperresponsiveness with beta2-adrenoceptor (ADRB2) haplotypes. A population study. Am J Respir Crit Care Med. 1998;158:1968-1973. (Pubitemid 29008841)
16. Ulbrecht M, Hergeth MT, Wjst M, et al. Association of beta(2)-adrenoreceptor variants with bronchial hyperresponsiveness. Am J Respir Crit Care Med. 2000;161(2 Pt 1):469-474. (Pubitemid 30129454)
17. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999; 286: 487-491.
18. Daly AK. Pharmacogenetics of the cytochromes P450. Curr Top Med Chem 2004;4(16):1733-1744.
19. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6-13. (Pubitemid 40220611)
20. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229-243.
21. Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol. 2000;10:27-34.
22. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype-a major determinant of metoprolol metabolism and response. N Engl J Med. 1982;307:1558-1560. (Pubitemid 13245431)
23. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351(27):2827-2831. Erratum in: N Engl J Med. 2005;352:638. (Pubitemid 40051906)
24. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001;52:349-355
25. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913-958. (Pubitemid 35168437)
26. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284-295. (Pubitemid 27058401)
27. Bertilsson L. Geographical interracial differences in polymorphic drug oxidation-current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet. 1995; 29:192-209.
28. Takada K, Arefayene M, Desta Z, et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum. 2004;50:2202-2210. (Pubitemid 38924398)
29. Lehmann DF, Medicis JJ, Franklin PD. Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer. J Clin Pharmacol. 2003;43:1316-1323.
30. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998;129:1027-1030. (Pubitemid 29005826)
31. Higuchi K, Tanabe S, Koizumi W, et al. An extensive metabolizer with recurrent ulcer responding to high dose of lansoprazole. Hepatogastroenterology. 2004;51:774-776. (Pubitemid 38590962)
32. Chou WH, Yan FX, Robbins-Weilert DK, et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem. 2003;49:542-551. (Pubitemid 36379518)
33. Heller T, Kirchheiner J, Armstrong VW, Luthe H, Brockmoller J, Oellerich M. Assessment Of AmpliChip CYP450 based CYP2D6-genotyping and phenotype prediction compared to PCRRFLP-genotyping and phenotyping by metoprolol pharmacokinetics. Ther Drug Monit. 2005;27:221, A43.
34. Ishida S, Soyama A, Saito Y, et al. Determination of CYP2D6 gene alleles by the CYP450 probe array using the Affymetrix GeneChip system: comparison with sequencing results. Drug Metab Pharmacokinet. 2002;17:157-160.
35. Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology. 2005;102: 543-549.
36. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66:15-27.
37. Seryx. LLC. Signature genetics: the know how to be well. Available at: http://www.signaturegenetics.com/sgtiles/en/download/physician-nb-5684.pdf. Accessed June 14, 2005.
38. Genelex Corporation. Health and DNA. Available at: http://www. healthanddna.com/. Accessed June 15, 2005.
39. Barrett S, Hall H. Dubious genetic testing. Quackwatch Web site. Available at: http://www.quackwatch.org/01QuackeryRelatedTopics/Tests/genomics. html. Accessed June 17, 2005.
40. Genaissance Pharmaceuticals, Inc. Pharmacogenomic support. Available at: http://www.dna.com/products-services/pgx-support-dd.html. Accessed June 15, 2005.
41. DxS Ltd. Genetwork. Available at: http://www.dxsgenotyping.com/genetwork. htm. Accessed June 15, 2005.
42. Third Wave Technologies, Inc. Proprietary invader technology. Available at: http://www.twt.com/invader-tech/inv-tech.htm. Accessed June 15, 2005.
43. GE HealthCare. CodeLink System: bioarrays for gene expression & SNP analysis. Available at: http://www1.amershambiosciences.com/APTRIX/upp 01077.nsf/Content/codelink-bioarray-system. Accessed June 9, 2005.
44. Gentris Corporation. Diagnostic products. Available at: http://www.gentris.com/diagnostic/. Accessed June 15, 2005.
45. Voora D, Eby C, Linder MW, et al. Prospective dosing of warfarin based on cytochrome P-4502C9 genotype. Thromb Haemost. 2005;93:700-705. (Pubitemid 40485406)
46. Veenstra DL, Blough DK, Higashi MK, et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther. 2005;77:353-364.
47. Impaired (S)-warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9. Pharmacogenetics.1994;4:39-42.
48. Kirchheiner J, Brockmoller J, Meineke I, et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther. 2002;71:286-296. (Pubitemid 34311458)
49. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P4502C9 polymorphisms. Clin Pharmacol Ther. 2005;77:1-16. (Pubitemid 40089477)
50. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen, PJ, Kivisto KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther. 2002;72:326-332. (Pubitemid 35052992)
51. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P4502C9 polymorphisms. Clin Pharmacol Ther. 2005;77:1-16. (Pubitemid 40089477)
52. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001;11:803-808. (Pubitemid 33151515)
53. Ohkusa T, Maekawa T, Arakawa T, et al. Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. Aliment Pharmacol Ther. 2005;21:1331-1339. (Pubitemid 40813679)
54. Kirsch C, Schneider-Brachert W, Grossmann D, et al. The efficacy of omeprazole/esomeprazole-based firstline and rescue therapies for treatment of Helicobacter pylori infection is not affected by polymorphisms of cytochrome P450-2C19. Gastroenterology. 2004;126(suppl. 2): A189.
55. Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazolebased quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther. 2004;76:201-209. (Pubitemid 39221794)
56. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy. 2003;23:460-471. (Pubitemid 36384325)
57. Poulsen L, Brosen K, ArendtNielsen L, Gram LF, Elbaek K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol. 1996;51:289-295. (Pubitemid 26422976)
58. Yue QY, Alm C, Svensson JO, Sawe J. Quantification of the O- and Ndemethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators. Ther Drug Monit. 1997;19:539-542. (Pubitemid 28116832)
59. Liou YJ, Wang YC, Bai YM, et al. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology. 2004; 49:167-173.
60. Grasmader K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol. 2004;60:329-336. (Pubitemid 39062319)
61. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473. (Pubitemid 38903502)
62. Kirchheiner J, Heesch C, Bauer S, et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2004;76:302-312. (Pubitemid 39313120)
63. Zineh I, Beitelshees AL, Gaedigk A, et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther. 2004;76:536-544. (Pubitemid 39601544)